Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 126, Issue 10, pp 549–559 | Cite as

Positron-emission tomography with [18F]fluorodeoxyglucose

Part I. Biochemical uptake mechanism and its implication for clinical studies
  • E. K. J. Pauwels
  • E. J. C. Sturm
  • E. Bombardieri
  • F. J. Cleton
  • M. P. M. Stokkel
REVIEW

Abstract

Over the past decades, Positron Emission Tomography has opened a new field of imaging. Nowadays, this technique is being used for diagnosing, staging disease as well as for prognostic stratification and monitoring therapy. In this respect, [18F]fluorodeoxyglucose (FdGlc) is by far the most commonly used PET agent. Many factors have been identified being responsible for a high uptake of this agent in malignancy. However, additional factors such as tumour treatment may interfere with the uptake mechanism. Knowledge of all these factors is a prerequisite for an optimal interpretation of PET studies and, consequently, for a reliable judgement of tumour status. In this article, a review is given of the factors influencing FdGlc uptake and the implications for clinical studies.

Keywords PET FDG Uptake mechanism Malignancy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • E. K. J. Pauwels
    • 1
  • E. J. C. Sturm
    • 1
  • E. Bombardieri
    • 3
  • F. J. Cleton
    • 2
  • M. P. M. Stokkel
    • 1
  1. 1.Leiden University Medical Centre, Division of Nuclear Medicine, C4-Q, P.O. Box 9600, 2300 RC, Leiden, The Netherlands e-mail: pauwels@mail.medfac.leidenuniv.nl Tel.: +31-71-526-3475; Fax: +31-71-526-6751NL
  2. 2.Leiden University Medical Centre, Division of Clinical Oncology, Leiden, The NetherlandsNL
  3. 3.Instituto Nazionale per lo Studio e la Cura dei Tumori, Milano, ItalyIT

Personalised recommendations